These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 4074432

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation.
    Kawamura K, Watanabe K, Kimura Y.
    Arzneimittelforschung; 1985; 35(7A):1149-54. PubMed ID: 4074427
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

  • 11. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
    Shintani S, Watanabe K, Kawamura K, Mori T, Tani T, Toba Y, Sasabe H, Nakagiri N, Hongoh O, Fujita S.
    Arzneimittelforschung; 1985; 35(7A):1163-72. PubMed ID: 3000392
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers.
    Niki T, Mori H.
    Arzneimittelforschung; 1985; 35(7A):1173-85. PubMed ID: 4074430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.
    Akiyama H, Kudo S, Shimizu T.
    Arzneimittelforschung; 1985; 35(7A):1124-32. PubMed ID: 4074423
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.
    Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y.
    Arzneimittelforschung; 1987 May; 37(5):563-6. PubMed ID: 2956957
    [Abstract] [Full Text] [Related]

  • 17. The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography.
    Usuda N, Nagata T, Naka M, Hidaka H.
    Arzneimittelforschung; 1985 May; 35(7A):1141-3. PubMed ID: 4074425
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Physico-chemical properties and stability of cilostazol.
    Shimizu T, Osumi T, Niimi K, Nakagawa K.
    Arzneimittelforschung; 1985 May; 35(7A):1117-23. PubMed ID: 4074422
    [Abstract] [Full Text] [Related]

  • 20. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery.
    Bach J, Kammerer I, Isgro F, Haubelt H, Vogt A, Saggau W, Hellstern P.
    Platelets; 2009 May; 20(3):150-7. PubMed ID: 19437331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.